Researchers at AACR discussed what's next for the drug class, given the disappointing activity of tiragolumab with Tecentriq ...

The nonprofit says its pipeline offers more affordable and accessible therapeutics, including point-of-care CAR-T cell therapy for leukemia and lymphoma.

The firm enrolled the first patient at Florida's BayCare Morton Plant Hospital, and the study procedure went according to protocol, per an investigator.

The firm is expecting Phase III readouts this year for its FGFR2b drug bemarituzumab and is advancing a second KRAS inhibitor to the clinic.

NEW YORK – DCx Biotherapeutics on Thursday said it acquired rights to certain technology platforms and small molecule therapeutic programs from Repare Therapeutics to accelerate the discovery and ...

The company said it took financial hits from the Inflation Reduction Act's Medicare Part D redesign, which included higher ...

The companies will analyze RNA sequencing data from Scipher to identify biomarkers for patient stratification and drug development.

The clinical trial will include nearly 150 patients with advanced hepatocellular carcinoma that expresses glypican-3.

When patients with solid tumors had the same liquid- and tissue-based test findings, patients had better outcomes on molecular tumor board-guided therapy.

Most adults in the US would take a blood test to assess whether they will develop Alzheimer's, according to the survey, ...

The RAS(ON) inhibitor shrunk tumors in around 60 percent of patients with KRAS G12D mutations, according to a study presented at AACR's annual meeting.